JP2024516098A5 - - Google Patents

Info

Publication number
JP2024516098A5
JP2024516098A5 JP2023561864A JP2023561864A JP2024516098A5 JP 2024516098 A5 JP2024516098 A5 JP 2024516098A5 JP 2023561864 A JP2023561864 A JP 2023561864A JP 2023561864 A JP2023561864 A JP 2023561864A JP 2024516098 A5 JP2024516098 A5 JP 2024516098A5
Authority
JP
Japan
Prior art keywords
amino acid
acid sequence
seq
sequence represented
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023561864A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024516098A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2022/086842 external-priority patent/WO2022218380A1/zh
Publication of JP2024516098A publication Critical patent/JP2024516098A/ja
Publication of JP2024516098A5 publication Critical patent/JP2024516098A5/ja
Pending legal-status Critical Current

Links

JP2023561864A 2021-04-15 2022-04-14 Bcmaを標的とする多重特異性抗体 Pending JP2024516098A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202110405638.3 2021-04-15
CN202110405638 2021-04-15
PCT/CN2022/086842 WO2022218380A1 (zh) 2021-04-15 2022-04-14 靶向bcma的多特异性抗体

Publications (2)

Publication Number Publication Date
JP2024516098A JP2024516098A (ja) 2024-04-12
JP2024516098A5 true JP2024516098A5 (cg-RX-API-DMAC7.html) 2025-03-18

Family

ID=83640152

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023561864A Pending JP2024516098A (ja) 2021-04-15 2022-04-14 Bcmaを標的とする多重特異性抗体

Country Status (12)

Country Link
US (1) US20240182592A1 (cg-RX-API-DMAC7.html)
EP (1) EP4324853A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024516098A (cg-RX-API-DMAC7.html)
KR (1) KR20230170721A (cg-RX-API-DMAC7.html)
CN (1) CN117062840A (cg-RX-API-DMAC7.html)
AU (1) AU2022256638A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023020341A2 (cg-RX-API-DMAC7.html)
CA (1) CA3214012A1 (cg-RX-API-DMAC7.html)
IL (1) IL307308A (cg-RX-API-DMAC7.html)
MX (1) MX2023011923A (cg-RX-API-DMAC7.html)
TW (1) TW202304963A (cg-RX-API-DMAC7.html)
WO (1) WO2022218380A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4201960A4 (en) * 2020-08-20 2024-09-04 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. BCMA-BINDING SINGLE MOLECULE WITH VARIABLE DOMAIN AND ANTIGEN-BINDING MOLECULE
WO2022037527A1 (zh) * 2020-08-20 2022-02-24 正大天晴药业集团股份有限公司 结合bcma的单可变结构域及抗原结合分子
JP2026513451A (ja) * 2023-04-24 2026-04-27 正大天晴▲藥▼▲業▼集▲団▼股▲フン▼有限公司 c-Metを標的とする多重特異性抗体
CN119119246B (zh) * 2024-06-26 2025-10-10 中国农业科学院兰州兽医研究所(中国动物卫生与流行病学中心兰州分中心) 一种抗非洲猪瘟病毒k205r蛋白的纳米抗体及应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013246443B2 (en) * 2012-04-11 2017-04-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric antigen receptors targeting B-cell maturation antigen
PL3177643T3 (pl) * 2014-08-04 2019-09-30 F.Hoffmann-La Roche Ag Dwuswoiste cząsteczki wiążące antygen aktywujące komórki T
TWI811023B (zh) * 2015-08-17 2023-08-01 美商健生生物科技公司 抗bcma抗體,結合bcma及cd3之雙特異性抗原結合分子及其用途
PL3896091T3 (pl) 2016-08-10 2024-04-29 Legend Biotech Ireland Limited Chimeryczne receptory antygenowe nakierowane na bcma i sposoby ich zastosowania
US11124577B2 (en) * 2016-11-02 2021-09-21 Engmab Sàrl Bispecific antibody against BCMA and CD3 and an immunological drug for combined use in treating multiple myeloma
CN110891971B (zh) * 2017-06-20 2024-01-12 特尼奥生物股份有限公司 仅有重链的抗bcma抗体
KR20200142525A (ko) 2018-04-05 2020-12-22 노파르티스 아게 암에 대한 삼중특이성 결합 분자 및 이의 용도
BR112021008486A2 (pt) * 2018-11-01 2021-10-26 Shandong New Time Pharmaceutical Co., Ltd Anticorpo biespecífico e seu uso
CN110551221B (zh) * 2019-07-02 2021-03-05 广州爱思迈生物医药科技有限公司 一种双特异性抗体及其制备方法与应用
CN112574308A (zh) * 2019-09-30 2021-03-30 和铂医药(苏州)有限公司 靶向bcma的抗体、双特异性抗体及其用途
EP4201960A4 (en) * 2020-08-20 2024-09-04 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. BCMA-BINDING SINGLE MOLECULE WITH VARIABLE DOMAIN AND ANTIGEN-BINDING MOLECULE
WO2022037527A1 (zh) * 2020-08-20 2022-02-24 正大天晴药业集团股份有限公司 结合bcma的单可变结构域及抗原结合分子
CN112794916B (zh) * 2021-04-08 2021-08-10 正大天晴药业集团南京顺欣制药有限公司 三特异性抗原结合构建体及构建方法和应用

Similar Documents

Publication Publication Date Title
CN112955471B (zh) Cd3抗体及其药物用途
CN114502591B (zh) 靶向bcma的抗体、双特异性抗体及其用途
TWI874613B (zh) 微型導引和導航控制(miniGNC)類抗體蛋白及其製造和使用方法
CN110520445B (zh) 抗pd-l1/抗pd-1天然抗体结构样异源二聚体形式双特异抗体及其制备
BR112019016204A2 (pt) anticorpo ou fragmento de ligação a antígeno do anticorpo, polinucleotídeo, vetor, célula, imunócito artificial, métodos para produzir um anticorpo ou um fragmento de ligação a antígeno do anticorpo, para produzir uma molécula que se liga ao cd3 humano e cd3 de macaco cinomolgo e ao gprc5d humano, composição medicinal para tratamento e/ou prevenção, moléculas tendo atividade de ligação a antígeno e que se ligam ao cd3 humano e cd3 de macaco cinomolgo e ao gprc5d humano, e, usos para preparar um medicamento para tratar e/ou prevenir um câncer, para induzir citotoxicidade para as células expressando gprc5d e para redirecionamento de células t para as células expressando gprc5d
EP3561057A1 (en) Anti-cd3 antibody, and molecule containing said antibody
JP2021524478A5 (cg-RX-API-DMAC7.html)
WO2016197497A1 (zh) 一种抗pd-1的单克隆抗体及其获得方法
CN106632674A (zh) 一种抗pd-1单克隆抗体、其药物组合物及其用途
JP2022533538A5 (cg-RX-API-DMAC7.html)
WO2020114479A1 (zh) 多特异性蛋白分子
CA2875451A1 (en) Antibody against transporter and use thereof
WO2019196309A1 (zh) 抗pd-l1抗体及其用途
AU2026202717A1 (en) Anti c-met antibodies
JP2024540148A5 (cg-RX-API-DMAC7.html)
CA3022961A1 (en) Anti-kv1.3 antibodies, and methods of production and use thereof
JP2023506834A5 (cg-RX-API-DMAC7.html)
CN112236456B (zh) 新型双特异性pd-1/lag-3抗体分子
JP2024516621A5 (cg-RX-API-DMAC7.html)
US12606628B2 (en) Antibodies targeting integrin beta-2
CN113549152B (zh) 一种抗basigin人源化抗体及其应用
IL295993A (en) Anti-cd19 antibodies and methods of using and making thereof
CN120040594B (zh) 一种靶向flt3基因编辑通用型car-t细胞的制备方法和应用
WO2025146161A1 (en) Antibody, antigen-binding fragment and medical use thereof
WO2024131846A1 (en) Antibody, antigen-binding fragment thereof, and pharmaceutical use thereof